Document 0594
 DOCN  M9610594
 TI    Virologic parameters as surrogate markers for clinical outcome in HIV-1
       disease: verification, variation, and validation.
 DT    9601
 AU    Reichelderfer PS; Coombs RW; NIH, NIAID, Division of AIDS, Bethesda, MD
       20892, USA.
 SO    J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 2:S19-24.
       Unique Identifier : AIDSLINE MED/96033808
 AB    The criteria used to evaluate which virologic measurements are used to
       monitor HIV-1 infection should include an assessment of verification,
       variation, and validation. Rationale for use should first be based on
       understanding the role of the measurement in the pathogenesis of the
       disease. Subsequently, the prevalence of the measurement, an
       understanding of its intrinsic variation, and ease of use will determine
       the utility of the measure. The usefulness of the measurement will
       depend on its validation in relation to disease prognosis, antiviral
       activity, and antiviral efficacy.
 DE    Biological Markers  Disease Progression  Human  HIV Infections/DRUG
       THERAPY/*VIROLOGY  *HIV-1/PHYSIOLOGY  Prognosis  Reproducibility of
       Results  Support, U.S. Gov't, P.H.S.  Treatment Outcome  JOURNAL ARTICLE
       REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).